 PDS Biotechnology Corporation NASDAQ: PDSB will be reporting preliminary Phase 2 clinical data of its lead compound PDS0101 for the treatment of advanced HPV-associated cancers in patients whose cancer has returned or progressed after treatment at the upcoming American Society of Clinical Oncology ASCO 2021 Annual Meeting on June 4-8. The study is being performed under a collaboration agreement with the National Cancer Institute NCI. 